Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure

• DOI: 10.1111/jgh.16790
• Publication Date: 2024-11-05T01:34:24Z
• Authors: Yoko Yamamoto; Ichiro Takeuchi; Hirotaka Shimizu; Hiroki Fujikawa; Masanori Toda; Eri Miyata; Hiroaki To; Satoru Nagata; Katsuhiro Arai
• Keywords: Interquartile range; Ustekinumab; Discontinuation

Abstract Background and Aim Only a few studies have reported the long‐term effects of ustekinumab on pediatric Crohn's disease. Therefore, this study aimed to describe clinical endoscopic outcomes its safety profile in pediatric‐onset disease with anti‐tumor necrosis factor failure. Methods Medical records patients whom therapy failed treatment was initiated from 2017 2022 at Japanese tertiary children's hospital were retrospectively reviewed. The primary outcome continuation rates weeks 8, 52, 106. secondary steroid‐free remission 106, changes Simple Endoscopic Score for Disease, adverse events during follow‐up. Results Forty‐three enrolled. median ages diagnosis introduction 9.7 (interquartile range: 6.7–13.0) years 13.6 8.0–16.0) years. follow‐up period 136 102–172) weeks. 100%, 91%, 80% respectively. incidence discontinuation 6.2% per patient‐year 44%, 71%, Disease last significantly decreased ( P < 0.01), acceptable. Conclusions Ustekinumab appeared effective maintaining improvement